Advertisements
Feeds:
Posts
Comments

Archive for the ‘Cardiac and Cardiovascular Surgical Procedures’ Category


Cardiac Medical Devices Pioneer, Earl E. Bakken, Medtronic Co-founder, the developer of the first external, battery-powered, transistorized pacemaker, died at 94 on 10/21/2018 in Hawaii

Reporter: Aviva Lev-Ari, PhD, RN

 

Earl Bakken was born to Florence and Osval Bakken on January 10, 1924, in Minneapolis. After serving as a radar instructor in World War II, Bakken earned a degree in electrical engineering at the University of Minnesota.

In the late 1950’s, Bakken developed the first external, wearable, battery-powered, transistorized heart pacemaker, and commercialized the first implantable pacemaker in 1960. Medtronic grew rapidly from there; today its medical products and devices improve the lives of two people every second.

Earl with five-year-old pacemaker recipient Lyla Koch in 1984

Image Sourcehttp://www.medtronic.com/us-en/about/news/celebrating-earl-bakken.html

CELEBRATING EARL BAKKEN

Legendary Medtronic co-founder passes away in Hawaii.

Earl Bakken, Co-founder, Medtronic, died at 94

Image Sourcehttp://www.medtronic.com/us-en/about/news/celebrating-earl-bakken.html

The business struggled, but while servicing medical equipment, Bakken and Hermundslie built relationships with doctors at university hospitals in Minneapolis. There they met C. Walton Lillehei, a young staff surgeon who would later become famous for pioneering open-heart surgery. Following a blackout in the Twin Cities that caused the death of an infant, Lillehei asked Bakken to come up with a solution. He responded by adapting a circuit described in Popular Electronics magazine to create the first external wearable, battery-powered pacemaker, replacing the large, alternating current-powered pacemakers that were in use at the time.

The original Medtronic "Garage Gang" poses in front of Medtronic Operational Headquarters in Fridley, Minnesota.

The Garage Gang

Standing: Dale Blosberg, Norman Hagfors, Earl Hatten. Seated: John Bravis, Earl Bakken, Louis Leisch

They expanded services to other medical technology. Then in 1960, the first implantable pacemaker was implanted in a human patient. Bakken and Hermundslie reached a licensing agreement with the inventors, giving their small company exclusive manufacturing and marketing rights to the device, and Medtronic took off.

“Earl always had a vision of healthcare of not being about devices, about drugs, but about restoring people to full health,” said former Medtronic CEO Bill George. “And so from the very start he was focused on not implanting a device, but enabling people to live a full active life and he delivered that point of view to all Medtronic employees through The Mission.

A lifelong aspiration came true for Bakken in 2013, when Medtronic Philanthropy launched The Bakken Invitation to honor people who received medical devices, and who made an impact on the lives of others, through service and volunteerism. Bakken, who in his later years became a medical device patient, with a pacemaker, coronary stents and insulin pump, was fond of asking patients what they planned to do with their gift of “extra life.” Each year Bakken met with the honorees. “Their stories are a powerful reminder that we can all give back-no matter our current situation,” he said after meeting them in 2014.

Earl poses with recipients of the Bakken Invitation in 2013.Earl with Bakken Invitation recipients in 2013

Every year in December, Medtronic employees gather to mark another Bakken inspiration — the employee holiday program. The company invites patients from all over the world to share their stories of how medical technology has improved their lives. Hundreds of employees fill the Medtronic conservatory for the event, while thousands of others listen or watch via Medtronic TV.

Advertisements

Read Full Post »


Live 12:00 – 1:00 P.M  Mediterranean Diet and Lifestyle: A Symposium on Diet and Human Health : October 19, 2018

Reporter: Stephen J. Williams, Ph.D.

12.00 The Italian Mediterranean Diet as a Model of Identity of a People with a Universal Good to Safeguard Health?

Prof. Antonino De Lorenzo, MD, PhD.

Director of the School of Specialization in Clinical Nutrition, University of Rome “Tor Vergata”

It is important to determine how our bodies interacts with the environment, such as absorption of nutrients.

Studies shown here show decrease in life expectancy of a high sugar diet, but the quality of the diet, not just the type of diet is important, especially the role of natural probiotics and phenolic compounds found in the Mediterranean diet.

The WHO report in 2005 discusses the unsustainability of nutrition deficiencies and suggest a proactive personalized and preventative/predictive approach of diet and health.

Most of the noncommunicable diseases like CV (46%) cancer 21% and 11% respiratory and 4% diabetes could be prevented and or cured with proper dietary approaches

Italy vs. the US diseases: in Italy most disease due to environmental contamination while US diet plays a major role

The issue we are facing in less than 10% of the Italian population (fruit, fibers, oils) are not getting the proper foods, diet and contributing to as we suggest 46% of the disease

The Food Paradox: 1.5 billion are obese; we notice we are eating less products of quality and most quality produce is going to waste;

  •  growing BMI and junk food: our studies are correlating the junk food (pre-prepared) and global BMI
  • modern diet and impact of human health (junk food high in additives, salt) has impact on microflora
  • Western Diet and Addiction: We show a link (using brain scans) showing correlation of junk food, sugar cravings, and other addictive behaviors by affecting the dopamine signaling in the substantia nigra
  • developed a junk food calculator and a Mediterranean diet calculator
  • the intersection of culture, food is embedded in the Mediterranean diet; this is supported by dietary studies of two distinct rural Italian populations (one of these in the US) show decrease in diet
  • Impact of diet: have model in Germany how this diet can increase health and life expectancy
  • from 1950 to present day 2.7 unit increase in the diet index can increase life expectancy by 26%
  • so there is an inverse relationship with our index and breast cancer

Environment and metal contamination and glyphosate: contribution to disease and impact of maintaining the healthy diet

  • huge problem with use of pesticides and increase in celiac disease

12:30 Environment and Health

Dr. Iris Maria Forte, PhD.

National Cancer Institute “Pascale” Foundation | IRCCS · Department of Research, Naples, Italy

Cancer as a disease of the environment.  Weinberg’s hallmarks of Cancer reveal how environment and epigenetics can impact any of these hallmarks.

Epigenetic effects

  • gene gatekeepers (Rb and P53)
  • DNA repair and damage stabilization

Heavy Metals and Dioxins:( alterations of the immune system as well as epigenetic regulations)

Asbestos and Mesothelioma:  they have demonstrated that p53 can be involved in development of mesothelioma as reactivating p53 may be a suitable strategy for therapy

Diet, Tomato and Cancer

  • looked at tomato extract on p53 function in gastric cancer: tomato extract had a growth reduction effect and altered cell cycle regulation and results in apoptosis
  • RBL2 levels are increased in extract amount dependent manner so data shows effect of certain tomato extracts of the southern italian tomato (     )

Antonio Giordano: we tested whole extracts of almost 30 different varieties of tomato.  The tomato variety  with highest activity was near Ravela however black tomatoes have shown high antitumor activity.  We have done a followup studies showing that these varieties, if grow elsewhere lose their antitumor activity after two or three generations of breeding, even though there genetics are similar.  We are also studying the effects of different styles of cooking of these tomatoes and if it reduces antitumor effect

please see post https://news.temple.edu/news/2017-08-28/muse-cancer-fighting-tomatoes-study-italian-food

 

To follow or Tweet on Twitter please use the following handles (@) and hashtags (#):

@ handles


@S_H_R_O 

@SbarroHealth

@Pharma_BI 

@ItalyinPhilly

@WHO_Europe

@nutritionorg

# hashtags


#healthydiet

#MediterraneanDiet

#health

#nutrition

Please see related articles on Live Coverage of Previous Meetings on this Open Access Journal

Real Time Conference Coverage for Scientific and Business Media: Unique Twitter Hashtags and Handles per Conference Presentation/Session

LIVE – Real Time – 16th Annual Cancer Research Symposium, Koch Institute, Friday, June 16, 9AM – 5PM, Kresge Auditorium, MIT

Real Time Coverage and eProceedings of Presentations on 11/16 – 11/17, 2016, The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

Tweets Impression Analytics, Re-Tweets, Tweets and Likes by @AVIVA1950 and @pharma_BI for 2018 BioIT, Boston, 5/15 – 5/17, 2018

BIO 2018! June 4-7, 2018 at Boston Convention & Exhibition Center

LIVE 2018 The 21st Gabay Award to LORENZ STUDER, Memorial Sloan Kettering Cancer Center, contributions in stem cell biology and patient-specific, cell-based therapy

HUBweek 2018, October 8-14, 2018, Greater Boston – “We The Future” – coming together, of breaking down barriers, of convening across disciplinary lines to shape our future

Read Full Post »


Surgical Aortic Valve Replacement (SAVR) vs Transcatheter Aortic Valve Implantation (TAVI): Results Comparison for Prosthesis-Patient Mismatch (PPM) – adjusted outcomes, including mortality, heart failure (HF) rehospitalization, stroke, and quality of life, at 1 year

 

Reporter: Aviva Lev-Ari, PhD, RN

 

J Am Coll Cardiol. 2018 Sep 18. pii: S0735-1097(18)38287-1. doi: 10.1016/j.jacc.2018.09.001. [Epub ahead of print]

Prosthesis-Patient Mismatch in 62,125 Patients Following Transcatheter Aortic Valve Replacement: From the STS/ACC TVT Registry.

Abstract

BACKGROUND:

Prosthesis-patient mismatch (PPM) after surgical aortic valve replacement (AVR) for aortic stenosis is generally associated with worse outcomes. Transcatheter AVR (TAVR) can achieve a larger valve orifice and the effects of PPM after TAVR are less well studied.

OBJECTIVES:

The authors utilized the Society of Thoracic Surgeons/American College of Cardiology TVT (Transcatheter Valve Therapy) registry to examine the frequency, predictors, and association with outcomes of PPM after TAVR in 62,125 patients enrolled between 2014 and 2017.

METHODS:

On the basis of the discharge echocardiographic effective valve area indexed to body surface area, PPM was classified as severe (<0.65 cm2/m2), moderate (0.65 to 0.85 cm2/m2), or none (>0.85 cm2/m2). Multivariable regression models were utilized to examine predictors of severe PPM as well as adjusted outcomes, including mortality, heart failure (HF) rehospitalization, stroke, and quality of life, at 1 year in 37,470 Medicare patients with claims linkage.

RESULTS:

  • Severe and moderate PPM were present following TAVR in 12% and 25% of patients, respectively. Predictors of severe PPM included small (≤23-mm diameter) valve prosthesis, valve-in-valve procedure, larger body surface area, female sex, younger age, non-white/Hispanic race, lower ejection fraction, atrial fibrillation, and severe mitral or tricuspid regurgitation.
  • At 1 year, mortality was 17.2%, 15.6%, and 15.9% in severe, moderate, and no PPM patients, respectively (p = 0.02).
  • HF rehospitalization had occurred in 14.7%, 12.8%, and 11.9% of patients with severe, moderate, and no PPM, respectively (p < 0.0001).
  • There was no association of severe PPM with stroke or quality of life score at 1 year.

CONCLUSIONS:

Severe PPM after TAVR was present in 12% of patients and was associated with higher mortality and HF rehospitalization at 1 year. Further investigation is warranted into the prevention of severe PPM in patients undergoing TAVR.

KEYWORDS:

aortic stenosis; prosthesis–patient mismatch; transcatheter aortic valve replacement

PMID:
30257798
DOI:
10.1016/j.jacc.2018.09.001

SOURCE

https://www.ncbi.nlm.nih.gov/pubmed/30257798

 

Prior Meta Analysis Study

Ann Thorac Surg. 2016 Mar;101(3):872-80

 

Ann Thorac Surg. 2016 Mar;101(3):872-80. doi: 10.1016/j.athoracsur.2015.11.048. Epub 2016 Jan 29.

Prosthesis-Patient Mismatch After Transcatheter Aortic Valve Implantation.

Abstract

BACKGROUND:

We reviewed currently available studies that investigated prosthesis-patient mismatch (PPM) in transcatheter aortic valve implantation (TAVI) with a systematic literature search and meta-analytic estimates.

METHODS:

To identify all studies that investigated PPM in TAVI, MEDLINE and EMBASE were searched through August 2015. Studies considered for inclusion met the following criteria: the study population included patients undergoing TAVI and outcomes included at least post-procedural PPM prevalence. We performed three quantitative meta-analyses about (1) PPM prevalence after TAVI, (2) PPM prevalence after TAVI versus surgical aortic valve replacement (SAVR), and (3) late all-cause mortality after TAVI in patients with PPM versus patients without PPM.

RESULTS:

We identified 21 eligible studies that included data on a total of 4,000 patients undergoing TAVI. The first meta-analyses found moderate PPM prevalence of 26.7%, severe PPM prevalence of 8.0%, and overall PPM prevalence of 35.1%. The second meta-analyses of six studies, including 745 patients, found statistically significant reductions in moderate (p = 0.03), severe (p = 0.0003), and overall (p = 0.02) PPM prevalence after TAVI relative to SAVR. The third meta-analyses of five studies, including 2,654 patients, found no statistically significant differences in late mortality between patients with severe PPM and patients without PPM (p = 0.44) and between patients with overall PPM and patients without PPM (p = 0.97).

CONCLUSIONS:

Overall, moderate, and severe PPM prevalence after TAVI was 35%, 27%, and 8%, respectively, which may be less than that after SAVR. In contrast to PPM after SAVR, PPM after TAVI may not impair late survival.

Comment in

 

Other related studies published on TAVR, TAVI in this Open Access Online Scientific Journal include the following:

 

  • New method for performing Aortic Valve Replacement: Transmural catheter procedure developed at NIH, Minimally-invasive tissue-crossing – Transcaval access, abdominal aorta and the inferior vena cava

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2016/10/31/new-method-for-performing-aortic-valve-replacement-transmural-catheter-procedure-developed-at-nih-minimally-invasive-tissue-crossing-transcaval-access-abdominal-aorta-and-the-inferior-vena-cava/

 

  • Second in the United States to implant Edwards Newly FDA-Approved Aortic Valve “Intuity Elite” Sutureless Valve at Northwestern Medicine

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2016/10/13/second-in-the-united-states-to-implant-edwards-newly-fda-approved-aortic-valve-intuity-elite-sutureless-valve-at-northwestern-medicine/

 

  • Medtronic’s CoreValve System Sustains Positive Outcomes Through Two Years in Extreme Risk Patients

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2014/09/15/medtronics-corevalve-system-sustains-positive-outcomes-through-two-years-in-extreme-risk-patients/

 

  • One year Post-Intervention Mortality Rate: TAVR and AVR – Aortic Valve Procedures 6.7% in AVR, 11.0% in AVR with CABG, 20.7 in Transvascular (TV-TAVR) and 28.0% in Transapical (TA-TAVR) Patients

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2014/08/04/one-year-post-intervention-mortality-rate-tavr-and-avr-aortic-valve-procedures-6-7-in-avr-11-0-in-avr-with-cabg-20-7-in-transvascular-tv-tavt-and-28-0-in-transapical-ta-tavr-patients/

 

  • Developments on the Frontier of Transcatheter Aortic Valve Replacement (TAVR) Devices

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2014/01/26/developments-on-the-frontier-of-transcatheter-aortic-valve-replacement-tavr-devices/

 

  • Off-Label TAVR Procedures: 1 in 10 associated with higher in-hospital 30-day mortality, 1-year mortality was similar in the Off-Label and the On-Label groups

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2017/06/22/off-label-tavr-procedures-1-in-10-associated-with-higher-in-hospital-30-day-mortality-1-year-mortality-was-similar-in-the-off-lavel-and-the-on-label-groups/

 

  • First U.S. TAVR Patients Treated With Temporary Pacing Lead (Tempo Lead)

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2016/12/21/first-u-s-tavr-patients-treated-with-temporary-pacing-lead-tempo-lead/

 

  • SAPIEN 3 Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients with Severe Aortic Stenosis: One-Year Clinical Outcomes

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2016/07/14/sapien-3-transcatheter-aortic-valve-replacement-in-high-risk-and-inoperable-patients-with-severe-aortic-stenosis-one-year-clinical-outcomes/

 

  • TAVR with Sapien 3: combined all-cause death & disabling stroke rate was 8.4% and 16.6% for the surgery arm

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2016/04/05/tavr-with-sapien-3-combined-all-cause-death-disabling-stroke-rate-was-8-4-and-16-6-for-the-surgery-arm/

 

  • Hadassah Opens Israel’s First Heart Valve Disease Clinic

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2016/12/06/hadassah-opens-israels-first-heart-valve-disease-clinic/

  • Trans-apical Transcatheter Aortic Valve Replacement in a Patient with Severe and Complex Left Main Coronary Artery Disease (LMCAD)

Author: Larry H Bernstein, MD, FCAP and Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2013/06/17/management-of-difficult-trans-apical-transcatheter-aortic-valve-replacement-in-a-patient-with-severe-and-complex-arterial-disease/

 

  • Transcatheter Aortic Valve Replacement (TAVR): Postdilatation to Reduce Paravalvular Regurgitation During TAVR with a Balloon-expandable Valve

Curator: Larry H Bernstein, MD, FCAP and Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2013/06/17/postdilatation-to-reduce-paravalvular-regurgitation-during-transcatheter-aortic-valve-replacement/

 

  • Transcatheter Aortic-Valve Replacement for Inoperable Severe Aortic Stenosis


Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2012/09/03/transcatheter-aortic-valve-replacement-for-inoperable-severe-aortic-stenosis/

 

  • Updated Transcatheter Aortic Valve Implantation (TAVI): risk for stroke and suitability for surgery

Reporter: Aviva Lev-Ari, PhD,RN

https://pharmaceuticalintelligence.com/2012/08/07/transcatheter-aortic-valve-implantation-tavi-risky-and-costly-2/

 

  • The Centers for Medicare & Medicaid Services (CMS) covers transcatheter aortic valve replacement (TAVR) under Coverage with Evidence Development (CED)

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2012/06/19/the-centers-for-medicare-medicaid-services-cms-covers-transcatheter-aortic-valve-replacement-tavr-under-coverage-with-evidence-development-ced/

 

  • Investigational Devices: Edwards Sapien Transcatheter Aortic Heart Valve Replacement Transfemoral Deployment

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2012/06/10/investigational-devices-edwards-sapien-transcatheter-aortic-heart-valve-replacement-transfemoral-deployment/

 

  • Investigational Devices: Edwards Sapien Transcatheter Aortic Valve Transapical Deployment

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2012/06/04/investigational-devices-edwards-sapien-transcatheter-heart-valve/

 

 

Read Full Post »


Rhythm Management Device Hardware (Dual-chamber Pacemaker) coupled with BackBeat’s Cardiac Neuromodulation Therapy (CNT) bioelectronic therapy for Lowering Systolic Blood Pressure for patients with Pacemakers

Reporter: Aviva Lev-Ari, PhD, RN

 

BackBeat’s CNT is a bioelectronic therapy that immediately, substantially and chronically lowers blood pressure (BP) while simultaneously modulating the autonomic nervous system (ANS).  Mimicking the effects of multiple medications by reducing pre-load, after-load and sympathetic tone, it can be delivered using standard rhythm management device hardware such as dual-chamber pacemakers.

For more information: www.orchestrabiomed.com

October 2, 2018 — Two-year results of the Moderato I Study demonstrated immediate, substantial and sustained reduction in blood pressure when BackBeat cardiac neuromodulation therapy (CNT) was used in patients with persistent hypertension (office BP > 150mmHg). Patients in the study had persistent hypertension despite two or more anti-hypertensive medications and an indication for a pacemaker.

Results of the multicenter clinical trial were presented at the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference, Sept. 21-25 in San Diego, by Daniel Burkhoff, M.D., Ph.D., director, heart failure, hemodynamics and mechanical circulatory support research for the Cardiovascular Research Foundation (CRF).

“The clinical efficacy and safety data observed with BackBeat CNT in a patient population with a significant portion of isolated systolic disease is very promising. Hypertension affects over 70 percent of pacemaker patients. These patients could benefit substantially from a potent hypertension therapy such as BackBeat CNT that could be included in their already necessary pacemaker,” said Prof. Petr Neuzil, M.D., head of the Department of Cardiology of Na Homolce Hospital in Prague, Czech Republic and one of the principal investigators of the study.

The 27 patients that met the study inclusion criteria were implanted with BackBeat’s proprietary Moderato dual-chamber pacemaker that incorporates the BackBeat CNT algorithms. The primary safety and efficacy endpoint results of the study were as follows:

  • Efficacy Outcomes: Immediate, substantial and sustained reduction in blood pressure.
    • 14.2 mmHg decrease from baseline (p<0.001) in 24 hours ambulatory systolic blood pressure (AMB BP) at 3 months
    • 23.4 mmHg decrease from baseline (p < 0.001) in systolic blood pressure (SBP) sustained out to 2 years
  • High responder rate in a population where 78 percent of patients had isolated systolic hypertension.
    • 85 percent AMB BP reduced >5mmHg
    • 74 percent AMB BP reduced >10 mmHg
  • Safety Outcomes: The study met the safety endpoint.
    • Observed reduction in end systolic and diastolic volumes with no change to ejection fraction suggests improvement of cardiac function
    • Observed reduction in heart rate out to 2 years indicative of reduced sympathetic activity

“These statistically significant results demonstrate the potential for BackBeat CNT to be a broadly applicable therapy that substantially lowers blood pressure immediately and maintains reduced pressures for years,” commented Burkhoff. “It is rare to see a new therapy show such dramatic and sustained effects in such a small number of patients.”

To further investigate the efficacy and safety of BackBeat CNT for the treatment of hypertension, Orchestra BioMed is enrolling patients into a prospective, 1:1 randomized double-blind active treatment (BackBeat CNT) versus standard medical therapy trial, Moderato II. The study will enroll patients with uncontrolled blood pressure (office systolic > 140, day and AMB BP > 130 mmHg) treated with at least one anti-hypertension medication that are indicated for a dual-chamber pacemaker. The primary efficacy endpoint of the first cohort of the study is the comparison of the mean reduction in 24-hour systolic ambulatory blood pressure following 6 months of therapy between the treatment and the control. Primary safety endpoint is the rate of major adverse cardiac event (MACE) at 6 months between the treatment and control.  The company is expecting results on the first cohort of patients in 2019.

SOURCE

https://www.dicardiology.com/content/backbeat-cardiac-neuromodulation-therapy-reduces-blood-pressure-two-years?eid=333021707&bid=2258792

Read Full Post »


Pulmonary Valve Replacement and Repair: Valvuloplasty Device – Tissue (bioprosthetic) or mechanical valve;  Surgery type – Transcatheter Pulmonary Valve Replacement (TPVR) vs Open Heart, Valve Repair – Commissurotomy, Valve-ring Annuloplasty

 

Reporter: Aviva Lev-Ari, PhD, RN

Outcomes of Pulmonary Valve Replacement in 170 Patients With Chronic Pulmonary Regurgitation After Relief of Right Ventricular Outflow Tract Obstruction
Implications for Optimal Timing of Pulmonary Valve Replacement

Abstract

Objectives The objectives of this study were to evaluate outcomes of pulmonary valve replacement (PVR) in patients with chronic pulmonary regurgitation (PR) and to better define the optimal timing of PVR.

Background Although PVR is effective in reducing right ventricular (RV) volume overload in patients with chronic PR, the optimal timing of PVR is not well defined.

Methods A total of 170 patients who underwent PVR between January 1998 and March 2011 for chronic PR were retrospectively analyzed. To define the optimal timing of PVR, pre-operative and post-operative cardiac magnetic resonance imaging (MRI) data (n = 67) were analyzed.

Results The median age at the time of PVR was 16.7 years. Follow-up completeness was 95%, and the median follow-up duration was 5.9 years. Overall and event-free survival at 10 years was 98% and 70%, respectively. Post-operative MRI showed significant reduction in RV volumes and significant improvement in biventricular function. Receiver-operating characteristic curve analysis revealed a cutoff value of 168 ml/m2 for non-normalization of RV end-diastolic volume index (EDVI) and 80 ml/m2 for RV end-systolic volume index (ESVI). Cutoff values for optimal outcome (normalized RV volumes and function) were 163 ml/m2 for RV EDVI and 80 ml/m2 for RV ESVI. Higher pre-operative RV ESVI was identified as a sole independent risk factor for suboptimal outcome.

Conclusions Midterm outcomes of PVR in patients with chronic PR were acceptable. PVR should be considered before RV EDVI exceeds 163 ml/m2 or RV ESVI exceeds 80 ml/m2, with more attention to RV ESVI.

Key Words

Relief of right ventricular (RV) outflow tract obstruction in tetralogy of Fallot or similar physiology often results in pulmonary regurgitation (PR). The resultant chronic volume overload can lead to RV dilation, biventricular dysfunction, heart failure symptoms, arrhythmias, and sudden death (1–5). Pulmonary valve replacement (PVR) can lead to improvement in functional class and a substantial decrease or normalization of RV volumes (6,7). Other potential benefits of PVR are improvement in exercise capacity (8) and decrease in QRS duration (9). However, benefits of PVR have to be weighed against the risks of this procedure. Although operative mortality of PVR is low (6), post-operative morbidities are not negligible (10) and patients are exposed to the risk of repeat PVR (11–13). PVR is indicated when patients become symptomatic or at risk for life-threatening arrhythmias (14). For asymptomatic patients, there have been debates regarding the optimal timing of PVR (15–19). Magnetic resonance imaging (MRI) is a gold standard for evaluating RV volumes and function (20), and these MRI parameters can be used to decide the indications for PVR. Many studies dealing with changes in MRI parameters after PVR have been reported (7–9,21–26). However, most of them have a limitation of small patient numbers, and there are few studies suggesting the optimal timing of PVR (7–9). The objectives of this study were to evaluate outcomes of PVR performed in patients with chronic PR and to better define the optimal timing of PVR by analyzing MRI parameters.

SOURCE

Journal of the American College of Cardiology

http://www.onlinejacc.org/content/60/11/1005

 

Pulmonary valve repair and replacement at Mayo Clinic

 

Mayo Clinic’s approach

Types

Why it’s done

Pulmonary valve disease treatment depends on the severity of your condition, whether or not you’re experiencing signs and symptoms, and if your condition is getting worse.

Many types of pulmonary valve disease are caused by heart conditions present at birth (congenital heart disease). Types of pulmonary valve disease that may require treatment with pulmonary valve repair or pulmonary valve replacement include:

Pulmonary valve regurgitation is a leaky pulmonary valve. The leaky valve allows blood to flow backward into the heart rather than directly to the lungs for oxygen.

The most common cause of pulmonary valve regurgitation is pulmonary hypertension. Other causes of pulmonary valve regurgitation are congenital heart disease (specifically, tetralogy of Fallot or congenital pulmonary valve stenosis), bacterial infection of the heart (infective endocarditis), complications after heart surgery, and rarely rheumatic fever.

Pulmonary valve stenosis occurs when the pulmonary valve becomes thickened or obstructed, which makes it harder for it to open properly and for the heart to pump blood into the pulmonary artery and to the lungs.

The cause of pulmonary valve stenosis is usually unknown. It often affects children and may be caused by congenital heart disease or an infection in the mother during pregnancy. It can also occur in adults as a result of a rare type of cancer that affects the heart (carcinoid heart disease).

Pulmonary atresia is a congenital heart defect in which a child is born without a well-defined pulmonary valve. In pulmonary atresia, blood can’t flow from the right ventricle into the pulmonary artery. The only blood flow to the lungs is through an open passageway between the pulmonary artery and the main artery supplying blood to the body (aorta).

The cause is usually unknown. Children born with pulmonary atresia may also have other heart defects.

For some people with mild pulmonary valve disease without symptoms, careful monitoring under a doctor’s supervision may be all that’s needed.

But in many cases, pulmonary valve disease and dysfunction progress in adulthood and get worse without medical treatment. Most pulmonary valve conditions are mechanical problems that cannot be adequately treated with medications alone and will eventually require surgery to reduce symptoms and the risk of complications, such as heart failure, or death due to advanced heart failure or sudden cardiac arrest.

The decision to repair or replace a damaged pulmonary valve depends on many factors, including:

  • The severity of your pulmonary valve disease
  • Your age and overall health
  • Whether you need heart surgery to correct another heart problem in addition to pulmonary valve disease, such as another valve surgery, for example, tricuspid valve repair or replacement, so both conditions can be treated at once

In general and whenever possible, heart valve repair is the preferred option because it is associated with a lower risk of infection, preserves valve strength and function, and eliminates the need to take blood-thinning medications, which may be necessary with valve replacement.

But not all valves can be repaired, and heart valve repair surgery is often harder to do than valve replacement. Your best option will depend on your individual situation as well as the expertise and experience of your health care team.

Pulmonary valve repair and pulmonary valve replacement may be performed via traditional open-heart surgery, which involves a cut (incision) in the chest (sternotomy), or via minimally invasive methods that involve smaller incisions in the chest (hybrid approach) or a catheter-based approach.

What type of procedure you have depends on the severity of your pulmonary valve disease, overall health and whether you need additional heart surgery to treat other issues.

SOURCE

Transcatheter Pulmonary Valve Replacement (TPVR) at Cleveland Clinic

 

A number of patients with congenital heart disease have problems with their pulmonary valve, either since birth, or after cardiac surgery. For many patients, a valve replacement may be recommended.

Until the last decade replacing a faulty pulmonary valve could only be done with open heart surgery. Because all surgically implanted valves have a limited life-span, patients faced many surgeries over the course of their life to replace the pulmonary valve. The percutaneous, non-surgical option to replace the pulmonary valve has revolutionized the care of these patients.

Image Source: Medtronic, 2017

Who can benefit from TPVR?

Patients who may benefit from a transcatheter pulmonary valve include those with:

  • Tetralogy of Fallot who have had prior surgery but now have a leaky or narrowed pulmonary valve, especially if they have undergone a prior surgical replacement.
  • Patients with other underlying diagnoses who also have a surgically implanted pulmonary valve (such as a homograft or a bioprosthetic valve) that is no longer working well; including patients with truncus arteriosus, patients with aortic valve disease who have had a Ross procedure, and some patients with pulmonary stenosis or atresia.

The goals of transcatheter pulmonary valve replacement is to replace the pulmonary valve non-surgically and decrease the number of heart surgeries a patient will need over their life-time.

Evaluation

To see if you are a possible candidate for treatment with the transcatheter pulmonary valve, you’ll have a comprehensive evaluation by a multidisciplinary team. The evaluation focuses on the patient’s condition, anatomy, and management options and will include:

  • Physical exam.
  • Diagnostic tests including an echocardiogram, cardiac MRI, or cardiac CT scan (the latter if you cannot have an MRI due to, for example, having a pacemaker).

Treatment

There are 2 valves currently approved by the FDA for this indication, the Melody valve and the Edwards SAPIEN XT valve. Both are tissue valves that are sutured to a stent, which is a thin metal cylinder that is mounted on a balloon catheter.

TPVR Procedure

The procedure is performed in a pediatric and adult congenital cardiac catheterization lab by an interventional cardiologist with expertise in congenital cardiac interventions, utilizing fluoroscopy and angiography to see the anatomy and evaluate the function of the heart valves.

A catheter is placed through a small incision into the femoral vein (in the groin) or the jugular vein in the neck.

A compressed tissue heart valve is placed on a balloon catheter; advanced through the vein to the heart, and is positioned directly inside the diseased pulmonary valve. Once in position, the balloon is inflated expanding the stent and the valve is secured in place. The new valve immediately begins to work. The catheter is then removed.

Patients are observed overnight and discharged the following morning. Usually you can return to your normal activities in 7 days.

Physicians with expertise in catheter interventions for congenital heart disease have been performing this procedure at the Cleveland Clinic since 2010. Both the Melody valve and the Edwards SAPIEN valve have been used, depending on the size needed for a particular patient. No patient with underlying congenital heart disease has had a severe complication and no patient has required removal of the valve to date.

SOURCE

https://my.clevelandclinic.org/health/treatments/17571-transcatheter-pulmonary-valve-replacement-tpvr

 

Pulmonary Valve Surgery at John Hopkins 

Why doesn’t my heart valve work properly?

Heart InteriorFrom The Illustrated Field Guide to Congenital Heart Disease and Repair – Second Edition courtesy of Scientific Software Solutions Inc.

The valves in your heart may be damaged due to infection, rheumatic heart disease or birth (congenital) defects. The affected valve leaflets (cusps) may grow thick and brittle from scar tissue or calcium deposits, or they may become thin and weak resulting in an inefficient valve.

There are several terms referring to valve disease.

  • Stenosis – the opening of the valve becomes smaller, thus allowing less blood to flow through.
  • Regurgitation/Insufficiency (leaky valve) – the valve does not close properly and allows blood to flow backward as well as forward in the heart.

How will I feel?

Due to the damaged valve, your heart must work harder to pump blood throughout the body.  You may tire easily and feel short of breath with less activity or exercise.  You may experience an irregular heartbeat due to over-stretching of the heart muscle as in mitral stenosis, or dizziness and near fainting due to decreased blood flow to the brain as in aortic stenosis.

How will my valve be fixed?

Depending on the extent of your valve disease, you may need to have the valve repaired or replaced.  To repair the valve, your surgeon may perform a commissurotomy or implant a valve ring.  A commissurotomy is performed for a tight valve (stenosis).  The valve leaflets are cut to loosen the valve slightly, allowing blood to pass easily.  Another type of valve repair is a valve ring annuloplasty, which is sewn in place when the valve is leaking (regurgitant or insufficient).  The valve leaflets are tucked in place with the ring.

Often the valve cannot be repaired and the surgeon must replace the damaged valve with a tissue (bioprosthetic) or mechanical valve.  Tissue valve are valves from animals (e.g., cow, pig).  They generally do not require long-term anticoagulation and are not as durable as mechanical valves.  Mechanical valves are made from materials such as plastic or metal.  They require long-term anticoagulation and are considered extremely durable, lasting longer than tissue valves.

Your surgeon will discuss the need for repair or replacement of the valve with you prior to surgery as well as the type of valve (tissue or mechanical) should replacement be necessary.

Annuloplasty RingAnnuloplasty Ring

Tissue ValveTissue Valve

Mechanical ValveMechanical Valve

Valve Replacement Surgery: What else should I know?

Prevention of Valve Infection

To prevent an infection (endocarditis) from occurring around the new heart valve or ring, you should receive antibiotics before having any procedures that could permit bacteria to enter your body.  Among these procedures are:

  • All dental procedures (cleaning, filling, removing teeth, root canals, gum or ulcer treatment). You may use dental floss, In fact, we encourage you to reduce tartar with any approved method.
  • Surgical procedures such as colonoscopy, cystoscopy, or other surgical procedures.

SOURCE

https://www.hopkinsmedicine.org/heart_vascular_institute/conditions_treatments/treatments/valve_pulmonary.html

Read Full Post »


Are TAVR volume requirements limiting rural and minority access to this life-saving procedure, or are they still necessary for patient safety?

Reporter: Aviva Lev-Ari, PhD, RN

 

CMS Considers Changing TAVR Volume Requirements

Debate over transcatheter aortic valve replacement (TAVR) procedures continues as the Centers for Medicare and Medicaid Services (CMS) considers changing the status quo. Are TAVR volume requirements limiting rural and minority access to this life-saving procedure, or are they still necessary for patient safety?

In June 2018, cardiology news sources widely reported that CMS opened public comment on established volume requirements for hospitals and heart teams to perform TAVR. The Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) then met on July 25 to discuss the issue. A report in Cardiovascular Business suggested that the committee appeared split on the subject—especially in weighing the potential harms of limiting TAVR to only high volume hospitals.

Cases for and against TAVR volume requirements

The Case for TAVR Volume Requirements

For those on the side of maintaining TAVR volume requirements, the benefits are obvious—volume is associated with positive outcomes and lower rates of complications. In fact, a 2018 expert consensus document from four major cardiology societies actually supported increasing volume requirements to maintain a TAVR program, to ensure adequate data collection for statistically reliable quality metrics and quality assurance.

A new study published in September in JACC: Cardiovascular Interventions seems to add new weight to this argument—data collected from hospitals participating in the international TAVR registry showed volume to have a significant effect on patient safety. The findings suggested that a learning curve of at least 225 procedures was required for hospitals to perform TAVRs with the lowest mortality rates, and that low annual volume hospitals were associated with decreased procedural safety and higher patient mortality.

John D. Carroll, MD, of the University of Colorado School of Medicine wrote an editorial in the same publication arguing that there is a “danger of lowering TAVR quality of care” by relaxing or eliminating TAVR volume requirements. “This would create many new centers starting a new learning curve, result in more low-volume centers, and potentially diluting the case volume and advanced skills of established and high-volume centers,” he writes.

The Case Against TAVR Volume Requirements

While the case for TAVR volume requirements is strong, it does little to answer the central question of the opposing viewpoint—does the benefit of expanding TAVR access to rural areas outweigh the cost of allowing the procedure to be conducted in relatively inexperienced or low-volume centers?

It is difficult to capture data depicting how many patients with aortic stenosis go without valve replacement due to TAVR volume requirements, but the concern seems genuine. We continue to learn more about TAVR, but experts have already established the procedure as the “treatment of choice in the extreme-risk patient who cannot have surgery,” said Martin B. Leon, MD, FACC at a 2017 American College of Cardiology conference.

In this population, where surgical valve replacement is not an option, median life expectancy is increased from 11 months to almost 30 months with TAVR, according to Leon. Indeed, some experts like Deepak L. Bhatt, MD, MPH, FACC, believe that, regardless of surgical risk scores, patients over 80 should undergo TAVR rather than surgical valve replacements.

If TAVR volume requirements limit access to the procedure for this growing elderly population, the negative effects would be obvious. An Edwards Lifesciences resource about aortic stenosis states, “After the onset of symptoms, patients with severe aortic stenosis have a survival rate as low as 50% at 2 years.”

SOURCE

https://acp-online.org/tavr-volume-requirements-debate/

Read Full Post »


Top 100 of 415 articles published on PubMed in 2018 on TAVR

Reporter: Aviva Lev-Ari, PhD, RN

 

SOURCE

https://www.ncbi.nlm.nih.gov/pubmed  [2018 TAVR]

Select item 301029701.

Ninety-Day Readmissions of Bundled Valve Patients: Implications for Healthcare Policy.

Koeckert MS, Grossi EA, Vining PF, Abdallah R, Williams MR, Kalkut G, Loulmet DF, Zias EA, Querijero M, Galloway AC.

Semin Thorac Cardiovasc Surg2018 Aug 10. pii: S1043-0679(18)30168-0. doi: 10.1053/j.semtcvs.2018.07.017. [Epub ahead of print]

PMID:
30102970
Select item 300946422.

TAVR Vs. SAVR in Intermediate-Risk Patients: What Influences Our Choice of Therapy.

Still S, Szerlip M, Mack M.

Curr Cardiol Rep2018 Aug 9;20(10):82. doi: 10.1007/s11886-018-1026-3. Review.

PMID:
30094642
Select item 300945323.

Transcatheter aortic valve replacement in patients with severe aortic stenosis and heart failure.

Bavishi C, Kolte D, Gordon PC, Abbott JD.

Heart Fail Rev2018 Aug 9. doi: 10.1007/s10741-018-9726-8. [Epub ahead of print] Review.

PMID:
30094532
Select item 300930574.

Disarming the Ticking Time Bomb: Post-Procedure Electrocardiography Predictors of High-Degree Conduction Disturbances After Transcatheter Aortic Valve Replacement.

Nazif TM, Chen S, Kodali SK.

JACC Cardiovasc Interv2018 Aug 13;11(15):1527-1530. doi: 10.1016/j.jcin.2018.07.003. No abstract available.

PMID:
30093057
Select item 300930565.

Predictors of Advanced Conduction Disturbances Requiring a Late (≥48 H) Permanent Pacemaker Following Transcatheter Aortic Valve Replacement.

Mangieri A, Lanzillo G, Bertoldi L, Jabbour RJ, Regazzoli D, Ancona MB, Tanaka A, Mitomo S, Garducci S, Montalto C, Pagnesi M, Giannini F, Giglio M, Montorfano M, Chieffo A, Rodès-Cabau J, Monaco F, Paglino G, Della Bella P, Colombo A, Latib A.

JACC Cardiovasc Interv2018 Aug 13;11(15):1519-1526. doi: 10.1016/j.jcin.2018.06.014.

PMID:
30093056
Select item 300930556.

Immediate Post-Procedural 12-Lead Electrocardiography as Predictor of Late Conduction Defects After Transcatheter Aortic Valve Replacement.

Jørgensen TH, De Backer O, Gerds TA, Bieliauskas G, Svendsen JH, Søndergaard L.

JACC Cardiovasc Interv2018 Aug 13;11(15):1509-1518. doi: 10.1016/j.jcin.2018.04.011.

PMID:
30093055
Select item 300925577.

Von Willebrand factor and the aortic valve: Concepts that are important in the transcatheter aortic valve replacement era.

Ibrahim H, Rondina MT, Kleiman NS.

Thromb Res2018 Jul 30;170:20-27. doi: 10.1016/j.thromres.2018.07.028. [Epub ahead of print] Review.

PMID:
30092557
Select item 300893298.

Antiplatelet Treatment for Catheter-Based Interventions in High-Risk Patients: Current Guidelines and Expert Opinion.

Rath D, Gawaz M.

Hamostaseologie2018 Aug 8. doi: 10.1055/s-0038-1668165. [Epub ahead of print]

PMID:
30089329
Select item 300870259.

The Evolution of Echocardiographic Type and Anesthetic Technique for Transcatheter Aortic Valve Replacement at a High-Volume Transcatheter Aortic Valve Replacement Center.

Marino M, Lilie CJ, Culp WC Jr, Schepel SR, Tippett JC.

J Cardiothorac Vasc Anesth2018 Jun 30. pii: S1053-0770(18)30468-3. doi: 10.1053/j.jvca.2018.06.022. [Epub ahead of print]

PMID:
30087025
Select item 3007961110.

Propensity matched comparison of in-hospital outcomes of TAVR vs. SAVR in patients with previous history of CABG: Insights from the Nationwide inpatient sample.

Nalluri N, Atti V, Patel NJ, Kumar V, Arora S, Nalluri S, Nelluri BK, Maniatis GA, Kandov R, Kliger C.

Catheter Cardiovasc Interv2018 Aug 5. doi: 10.1002/ccd.27708. [Epub ahead of print]

PMID:
30079611
Select item 3007956111.

Permanent pacemaker implantation after transcatheter aortic valve replacement in bicuspid aortic valve patients.

Xiong TY, Liao YB, Li YJ, Zhao ZG, Wei X, Tsauo JY, Xu YN, Feng Y, Chen M.

J Interv Cardiol2018 Aug 5. doi: 10.1111/joic.12546. [Epub ahead of print]

PMID:
30079561
Select item 3007952212.

Effect of transcatheter aortic valve replacement on left atrial function.

Truong VT, Chung E, Nagueh S, Kereiakes D, Schaaf J, Volz B, Ngo TNM, Mazur W.

Echocardiography2018 Aug 5. doi: 10.1111/echo.14109. [Epub ahead of print]

PMID:
30079522
Select item 3007679413.

TAVR 2.0: Collaborating to Measure, Assure, and Advance Quality.

Shahian DM, Gleason TG, Shemin RJ, Carroll JD, Mack MJ.

Ann Thorac Surg2018 Aug 1. pii: S0003-4975(18)31034-8. doi: 10.1016/j.athoracsur.2018.07.004. [Epub ahead of print] No abstract available.

PMID:
30076794
Select item 3007608114.

Low Iodine Contrast Injection for CT Acquisition Prior to Transcatheter Aortic Valve Replacement: Aorta Assessment and Screening for Coronary Artery Disease.

Hachulla AL, Noble S, Ronot M, Guglielmi G, de Perrot T, Montet X, Vallée JP.

Acad Radiol2018 Aug 1. pii: S1076-6332(18)30330-1. doi: 10.1016/j.acra.2018.06.016. [Epub ahead of print]

PMID:
30076081
Select item 3007532615.

Variation in post-TAVR antiplatelet therapy utilization and associated outcomes: Insights from the STS/ACC TVT Registry.

Sherwood MW, Vemulapalli S, Harrison JK, Dai D, Vora AN, Mack MJ, Holmes DR, Rumsfeld JS, Cohen DJ, Thourani VH, Kirtane A, Peterson ED.

Am Heart J2018 Jul 9;204:9-16. doi: 10.1016/j.ahj.2018.06.006. [Epub ahead of print]

PMID:
30075326
Select item 3006878516.

State of Transcatheter Aortic Valve Implantation in Spain Versus Europe and Non-European Countries.

Biagioni C, Tirado-Conte G, Rodés-Cabau J, Ryan N, Cerrato E, Nazif TM, Eltchaninoff H, Sondergaard L, Ribeiro HB, Barbanti M, Nietlispach F, De Jaegere P, Agostoni P, Trillo R, Jiménez-Quevedo P, D’Ascenzo F, Wendler O, Maluenda G, Chen M, Tamburino C, Macaya C, Leon MB, Nombela-Franco L.

J Invasive Cardiol2018 Aug;30(8):301-309.

Select item 3006493717.

Accuracy of predicted orthogonal projection angles for valve deployment during transcatheter aortic valve replacement.

Steinvil A, Weissman G, Ertel AW, Weigold G, Rogers T, Koifman E, Buchanan KD, Shults C, Torguson R, Okubagzi PG, Satler LF, Ben-Dor I, Waksman R.

J Cardiovasc Comput Tomogr2018 May 26. pii: S1934-5925(18)30130-8. doi: 10.1016/j.jcct.2018.05.017. [Epub ahead of print]

PMID:
30064937
Select item 3006277818.

Absence of Electrocardiographic Left Ventricular Hypertrophy is Associated with Increased Mortality After Transcatheter Aortic Valve Replacement.

Kampaktsis PN, Ullal AV, Swaminathan RV, Minutello RM, Kim L, Bergman GS, Feldman DN, Singh H, Chiu Wong S, Okin PM.

Clin Cardiol2018 Jul 30. doi: 10.1002/clc.23034. [Epub ahead of print]

Select item 3005825919.

Early and midterm outcomes of transcatheter aortic valve replacement in patients with bicuspid aortic valves.

Aalaei-Andabili SH, Beaver TM, Petersen JW, Anderson RD, Karimi A, Thoburn E, Kabir A, Bavry AA, Arnaoutakis GJ.

J Card Surg2018 Jul 29. doi: 10.1111/jocs.13775. [Epub ahead of print]

PMID:
30058259
Select item 3005725220.

The Incidence of Dysphagia Among Patients Undergoing TAVR With Either General Anesthesia or Moderate Sedation.

Mukdad L, Kashani R, Mantha A, Sareh S, Mendelsohn A, Benharash P.

J Cardiothorac Vasc Anesth2018 May 26. pii: S1053-0770(18)30373-2. doi: 10.1053/j.jvca.2018.05.040. [Epub ahead of print]

PMID:
30057252
Select item 3005685121.

Sex-Specific Differences in Outcome of Transcatheter or Surgical Aortic Valve Replacement.

Kaier K, von Zur Mühlen C, Zirlik A, Schmoor C, Roth K, Bothe W, Hehn P, Reinöhl J, Zehender M, Bode C, Stachon P.

Can J Cardiol2018 Aug;34(8):992-998. doi: 10.1016/j.cjca.2018.04.009. Epub 2018Apr 12.

PMID:
30056851
Select item 3005602322.

Hemodynamic monitoring by pulse contour analysis during trans-catheter aortic valve replacement: A fast and easy method to optimize procedure results.

Ristalli F, Romano SM, Stolcova M, Meucci F, Squillantini G, Valente S, Di Mario C.

Cardiovasc Revasc Med2018 Jul 19. pii: S1553-8389(18)30314-2. doi: 10.1016/j.carrev.2018.07.015. [Epub ahead of print]

PMID:
30056023
Select item 3005418823.

TAVR Versus SAVR in the Era of NSQIP.

Vadlamudi R, Duggan M.

J Cardiothorac Vasc Anesth2018 May 26. pii: S1053-0770(18)30370-7. doi: 10.1053/j.jvca.2018.05.037. [Epub ahead of print] No abstract available.

PMID:
30054188
Select item 3005090924.

Expanding TAVI to Low and Intermediate Risk Patients.

Voigtländer L, Seiffert M.

Front Cardiovasc Med2018 Jul 12;5:92. doi: 10.3389/fcvm.2018.00092. eCollection 2018. Review.

Select item 3004863225.

Albumin Is Predictive of 1-Year Mortality After Transcatheter Aortic Valve Replacement.

Hebeler KR, Baumgarten H, Squiers JJ, Wooley J, Pollock BD, Mahoney C, Filardo G, Lima B, DiMaio JM.

Ann Thorac Surg2018 Jul 23. pii: S0003-4975(18)31022-1. doi: 10.1016/j.athoracsur.2018.06.024. [Epub ahead of print]

PMID:
30048632
Select item 3004178326.

Bioprosthetic structural valve deterioration: How do TAVR and SAVR prostheses compare?

Aldalati O, Kaura A, Khan H, Dworakowski R, Byrne J, Eskandari M, Deshpande R, Monaghan M, Wendler O, MacCarthy P.

Int J Cardiol2018 Oct 1;268:170-175. doi: 10.1016/j.ijcard.2018.04.091.

PMID:
30041783
Select item 3003771727.

Exposure to glucocorticoids prior to transcatheter aortic valve replacement is associated with reduced incidence of high-degree AV block and pacemaker.

Oestreich B, Gurevich S, Adabag S, Kelly R, Helmer G, Raveendran G, Yannopoulos D, Biring T, Garcia S.

Cardiovasc Revasc Med2018 Jul 18. pii: S1553-8389(18)30311-7. doi: 10.1016/j.carrev.2018.07.012. [Epub ahead of print]

PMID:
30037717
Select item 3003742428.

Comparison of Hospital Outcomes of Transcatheter Aortic Valve Implantation With Versus Without Hypothyroidism.

Subahi A, Yassin AS, Adegbala O, Akintoye E, Abubakar H, Elmoghrabi A, Ibrahim W, Ajam M, Pahuja M, Weinberger JJ, Levine D, Afonso L.

Am J Cardiol2018 Jun 5. pii: S0002-9149(18)31197-4. doi: 10.1016/j.amjcard.2018.05.025. [Epub ahead of print]

PMID:
30037424
Select item 3003171929.

Arrhythmic Burden as Determined by Ambulatory Continuous Cardiac Monitoring in Patients With New-Onset Persistent Left Bundle Branch Block Following Transcatheter Aortic Valve Replacement: The MARE Study.

Rodés-Cabau J, Urena M, Nombela-Franco L, Amat-Santos I, Kleiman N, Munoz-Garcia A, Atienza F, Serra V, Deyell MW, Veiga-Fernandez G, Masson JB, Canadas-Godoy V, Himbert D, Castrodeza J, Elizaga J, Francisco Pascual J, Webb JG, de la Torre JM, Asmarats L, Pelletier-Beaumont E, Philippon F.

JACC Cardiovasc Interv2018 Aug 13;11(15):1495-1505. doi: 10.1016/j.jcin.2018.04.016. Epub 2018 Jul 18.

PMID:
30031719
Select item 3003171830.

Arrhythmias and Conduction Disturbances Following Transcatheter Aortic Valve Replacement: Out of Sight, Out of Mind?

Pighi M, Piazza N.

JACC Cardiovasc Interv2018 Aug 13;11(15):1506-1508. doi: 10.1016/j.jcin.2018.05.038. Epub 2018 Jul 18. No abstract available.

PMID:
30031718
Select item 3002924731.

Numerical Parametric Study of Paravalvular Leak Following a Transcatheter Aortic Valve Deployment Into a Patient-Specific Aortic Root.

Mao W, Wang Q, Kodali S, Sun W.

J Biomech Eng2018 Oct 1;140(10). doi: 10.1115/1.4040457.

PMID:
30029247
Select item 3002920732.

Comparative Fluid-Structure Interaction Analysis of Polymeric Transcatheter and Surgical Aortic Valves’ Hemodynamics and Structural Mechanics.

Ghosh R, Marom G, Rotman O, Slepian MJ, Prabhakar S, Horner M, Bluestein D.

J Biomech Eng2018 Jun 25. doi: 10.1115/1.4040600. [Epub ahead of print]

PMID:
30029207
Select item 3002830433.

Extended benefits of TAVR in young patients with low-intermediate risk score: proceed with care.

Doshi R.

EuroIntervention2018 Jul 20;14(4):e485. doi: 10.4244/EIJ-D-18-00236L. No abstract available.

Select item 3002830034.

Valve-in-valve TAVR using the SAPIEN 3 transcatheter heart valve: still plagued by patient-prosthesis mismatch.

Saxon JT, Cohen DJ, Feldman T.

EuroIntervention2018 Jul 20;14(4):e377-e379. doi: 10.4244/EIJV14I4A66. No abstract available.

Select item 3002573135.

The SAVI-TF Registry: 1-Year Outcomes of the European Post-Market Registry Using the ACURATE neo Transcatheter Heart Valve Under Real-World Conditions in 1,000 Patients.

Kim WK, Hengstenberg C, Hilker M, Kerber S, Schäfer U, Rudolph T, Linke A, Franz N, Kuntze T, Nef H, Kappert U, Zembala MO, Toggweiler S, Walther T, Möllmann H.

JACC Cardiovasc Interv2018 Jul 23;11(14):1368-1374. doi: 10.1016/j.jcin.2018.03.023.

Select item 3002557236.

Transcatheter Aortic Valve Replacement of Failed Surgically Implanted Bioprostheses: The STS/ACC Registry.

Tuzcu EM, Kapadia SR, Vemulapalli S, Carroll JD, Holmes DR Jr, Mack MJ, Thourani VH, Grover FL, Brennan JM, Suri RM, Dai D, Svensson LG.

J Am Coll Cardiol2018 Jul 24;72(4):370-382. doi: 10.1016/j.jacc.2018.04.074.

PMID:
30025572
Select item 3002410237.

Transcatheter valve-in-valve versus redo surgical aortic valve replacement for the treatment of degenerated bioprosthetic aortic valve: A systematic review and meta-analysis.

Tam DY, Vo TX, Wijeysundera HC, Dvir D, Friedrich JO, Fremes SE.

Catheter Cardiovasc Interv2018 Jul 19. doi: 10.1002/ccd.27686. [Epub ahead of print]

PMID:
30024102
Select item 3001983938.

Predicted magnitude of alternate access in the contemporary transcatheter aortic valve replacement era.

Rogers T, Gai J, Torguson R, Okubagzi PG, Shults C, Ben-Dor I, Satler LF, Waksman R.

Catheter Cardiovasc Interv2018 Jul 18. doi: 10.1002/ccd.27668. [Epub ahead of print]

PMID:
30019839
Select item 3001982839.

Slope of left ventricular filling as an index of valvular and paravalvular regurgitation in native and prosthetic aortic valves.

Makki N, Ghao X, Whitson B, Shreenivas S, Crestanello J, Lilly S.

Catheter Cardiovasc Interv2018 Jul 18. doi: 10.1002/ccd.27684. [Epub ahead of print]

PMID:
30019828
Select item 3001982240.

Is two better than one? Re-evaluating the surgical approval process for TAVR.

Shreenivas S, Lilly S, Reardon M, Answini GA, Kereiakes DJ.

Catheter Cardiovasc Interv2018 Jul 18. doi: 10.1002/ccd.27666. [Epub ahead of print] No abstract available.

PMID:
30019822
Select item 3001816741.

Improving the Diagnostic Performance of 18F-FDG PET/CT in Prosthetic Heart Valve Endocarditis.

Swart LE, Gomes A, Scholtens AM, Sinha B, Tanis W, Lam MGEH, van der Vlugt MJ, Streukens SAF, Aarntzen EHJG, Bucerius J, van Assen S, Bleeker-Rovers CP, van Geel PP, Krestin GP, van Melle JP, Roos-Hesselink JW, Slart RHJA, Glaudemans AWJM, Budde RPJ.

Circulation2018 Jul 17. pii: CIRCULATIONAHA.118.035032. doi: 10.1161/CIRCULATIONAHA.118.035032. [Epub ahead of print]

PMID:
30018167
Select item 3001752042.

Software-automated multidetector computed tomography-based prosthesis-sizing in transcatheter aortic valve replacement: Inter-vendor comparison and relation to patient outcome.

Baeßler B, Mauri V, Bunck AC, Pinto Dos Santos D, Friedrichs K, Maintz D, Rudolph T.

Int J Cardiol2018 Jul 9. pii: S0167-5273(18)32256-3. doi: 10.1016/j.ijcard.2018.07.008. [Epub ahead of print] No abstract available.

PMID:
30017520
Select item 3001751843.

Inflammation in aortic stenosis: Shaping the biomarkers network.

Schiattarella GG, Perrino C.

Int J Cardiol2018 Jul 6. pii: S0167-5273(18)33669-6. doi: 10.1016/j.ijcard.2018.07.026. [Epub ahead of print] No abstract available.

PMID:
30017518
Select item 3001728244.

Inter- and intra-observer repeatability of aortic annulus measurements on screening CT for transcatheter aortic valve replacement (TAVR): Implications for appropriate device sizing.

Knobloch G, Sweetman S, Bartels C, Raval A, Gimelli G, Jacobson K, Lozonschi L, Kohmoto T, Osaki S, François C, Nagle S.

Eur J Radiol2018 Aug;105:209-215. doi: 10.1016/j.ejrad.2018.06.003. Epub 2018 Jun 15.

PMID:
30017282
Select item 3001614745.

Atherosclerosis on CT Angiogram Predicts Acute Kidney Injury After Transcatheter Aortic Valve Replacement.

Kandathil A, Abbara S, Hanna M, Minhajuddin A, Wehrmann L, Merchant AM, Mills R, Fox AA.

AJR Am J Roentgenol2018 Jul 17:1-7. doi: 10.2214/AJR.17.19340. [Epub ahead of print]

PMID:
30016147
Select item 3001289046.

Transfemoral Implantation of the Acurate neo for the Treatment of Aortic Regurgitation.

Toggweiler S, Cerillo AG, Kim WK, Biaggi P, Lloyd C, Hilker M, Almagor Y, Cuculi F, Brinkert M, Kobza R, Muller O, Rück A, Corti R.

J Invasive Cardiol2018 Jul 15. pii: JIC2018715-3. [Epub ahead of print]

Select item 3000980047.

Suprasternal and Left Axillary Transcatheter Aortic Valve Replacement in Morbidly Obese Patients.

Olds A, Eudailey K, Nazif T, Vahl T, Khalique O, Lewis C, Hahn R, Leon M, Bapat V, Ahmed M, Kodali S, George I.

Ann Thorac Surg2018 Jul 13. pii: S0003-4975(18)30978-0. doi: 10.1016/j.athoracsur.2018.05.095. [Epub ahead of print]

PMID:
30009800
Select item 3000336648.

Transcatheter valve-in-valve implantation (VinV-TAVR) for failed surgical aortic bioprosthetic valves.

Wernly B, Zappe AK, Unbehaun A, Sinning JM, Jung C, Kim WK, Fichtlscherer S, Lichtenauer M, Hoppe UC, Alushi B, Beckhoff F, Wewetzer C, Franz M, Kretzschmar D, Navarese E, Landmesser U, Falk V, Lauten A.

Clin Res Cardiol2018 Jul 12. doi: 10.1007/s00392-018-1326-z. [Epub ahead of print]

PMID:
30003366
Select item 3000209949.

Myocardial Scar and Mortality in Severe Aortic Stenosis: Data from the BSCMR Valve Consortium.

Musa TA, Treibel TA, Vassiliou VS, Captur G, Singh A, Chin C, Dobson LE, Pica S, Loudon M, Malley T, Rigolli M, Foley JRJ, Bijsterveld P, Law GR, Dweck MR, Myerson SG, McCann GP, Prasad SK, Moon JC, Greenwood JP.

Circulation2018 Jul 12. pii: CIRCULATIONAHA.117.032839. doi: 10.1161/CIRCULATIONAHA.117.032839. [Epub ahead of print]

PMID:
30002099
Select item 2999613850.

Aortic Angulation and TAVR.

Gandotra P.

Cardiology2018 Jul 11;140(3):141-142. doi: 10.1159/000490094. [Epub ahead of print] No abstract available.

Select item 2998906851.

Endovascular repair of severe aortic coarctation, transcatheter aortic valve replacement for severe aortic stenosis, and percutaneous coronary intervention in an elderly patient with long term follow-up.

Fallatah R, Elasfar A, Amoudi O, Ajaz M, AlHarbi I, Abuelatta R.

J Saudi Heart Assoc2018 Jul;30(3):271-275. doi: 10.1016/j.jsha.2018.01.003. Epub 2018 Feb 9.

Select item 2998711952.

Impact of Rapid Ventricular Pacing on Outcome After Transcatheter Aortic Valve Replacement.

Fefer P, Bogdan A, Grossman Y, Berkovitch A, Brodov Y, Kuperstein R, Segev A, Guetta V, Barbash IM.

J Am Heart Assoc2018 Jul 9;7(14). pii: e009038. doi: 10.1161/JAHA.118.009038.

Select item 2998314253.

Imaging Evaluation for the Detection of Leaflet Thrombosis After Transcatheter Aortic Valve Replacement.

Zhao ZG, Wang MY, Jilaihawi H.

Interv Cardiol Clin2018 Jul;7(3):293-299. doi: 10.1016/j.iccl.2018.03.007. Epub 2018Jun 29. Review.

PMID:
29983142
Select item 2998314154.

Imaging Evaluation and Interpretation for Vascular Access for Transcatheter Aortic Valve Replacement.

Foley TR, Stinis CT.

Interv Cardiol Clin2018 Jul;7(3):285-291. doi: 10.1016/j.iccl.2018.03.006. Epub 2018Jun 29. Review.

PMID:
29983141
Select item 2998121455.

Echocardiography in transcatheter aortic (Core)Valve implantation: Part 2-Transesophageal echocardiography.

Naqvi TZ.

Echocardiography2018 Jul;35(7):1020-1041. doi: 10.1111/echo.14034. Review.

PMID:
29981214
Select item 2998029956.

Impact of patient-specific morphologies on sinus flow stasis in transcatheter aortic valve replacement: An in vitro study.

Hatoum H, Dollery J, Lilly SM, Crestanello J, Dasi LP.

J Thorac Cardiovasc Surg2018 Jun 7. pii: S0022-5223(18)31521-6. doi: 10.1016/j.jtcvs.2018.05.086. [Epub ahead of print]

PMID:
29980299
Select item 2997656857.

Malnutrition and Mortality in Frail and Non-Frail Older Adults Undergoing Aortic Valve Replacement.

Goldfarb M, Lauck S, Webb JG, Asgar AW, Perrault LP, Piazza N, Martucci G, Lachapelle K, Noiseux N, Kim DH, Popma JJ, Lefèvre T, Labinaz M, Lamy A, Peterson MD, Arora RC, Morais JA, Morin JF, Rudski L, Afilalo J; FRAILTY-AVR Investigators .

Circulation2018 Jul 5. pii: CIRCULATIONAHA.118.033887. doi: 10.1161/CIRCULATIONAHA.118.033887. [Epub ahead of print]

PMID:
29976568
Select item 2997636358.

Debris Heterogeneity Across Different Valve Types Captured by a Cerebral Protection System During Transcatheter Aortic Valve Replacement.

Schmidt T, Leon MB, Mehran R, Kuck KH, Alu MC, Braumann RE, Kodali S, Kapadia SR, Linke A, Makkar R, Naber C, Romero ME, Virmani R, Frerker C.

JACC Cardiovasc Interv2018 Jul 9;11(13):1262-1273. doi: 10.1016/j.jcin.2018.03.001.

PMID:
29976363
Select item 2997426459.

A Review of Alternative Access for Transcatheter Aortic Valve Replacement.

Young MN, Singh V, Sakhuja R.

Curr Treat Options Cardiovasc Med2018 Jul 4;20(7):62. doi: 10.1007/s11936-018-0648-5. Review.

PMID:
29974264
Select item 2997123860.

Transcatheter Aortic Valve Replacement and Concomitant Mitral Regurgitation.

Stähli BE, Reinthaler M, Leistner DM, Landmesser U, Lauten A.

Front Cardiovasc Med2018 Jun 19;5:74. doi: 10.3389/fcvm.2018.00074. eCollection 2018. Review.

Select item 2996942761.

Propensity matched comparison of clinical outcomes after transaortic versus transfemoral aortic valve replacement.

Chollet T, Marcheix B, Boudou N, Elbaz M, Campelo-Parada F, Bataille V, Bouisset F, Lairez O, Porterie J, Galinier M, Carrie D, Lhermusier T.

EuroIntervention2018 Jul 3. pii: EIJ-D-18-00168. doi: 10.4244/EIJ-D-18-00168. [Epub ahead of print]

Select item 2996827362.

Alternative access for transcatheter aortic valve replacement in older adults: A collaborative study from France and United States.

Damluji AA, Murman M, Byun S, Moscucci M, Resar JR, Hasan RK, Alfonso CE, Carrillo RG, Williams DB, Kwon CC, Cho PW, Dijos M, Peltan J, Heldman AW, Cohen MG, Leroux L.

Catheter Cardiovasc Interv2018 Jul 3. doi: 10.1002/ccd.27690. [Epub ahead of print]

PMID:
29968273
Select item 2996613163.

Does Aortic Angulation Impact Outcomes in TAVR.

Czarny MJ, Resar JR.

Cardiology2018;140(2):103-105. doi: 10.1159/000489697. Epub 2018 Jul 2. No abstract available.

PMID:
29966131
Select item 2996339164.

Transcaval transcatheter aortic valve replacement: a visual case review.

Muhammad KI, Tokarchik GC.

J Vis Surg2018 May 14;4:102. doi: 10.21037/jovs.2018.04.02. eCollection 2018.

Select item 2996107265.

Aortic Angulation Does Not Impact Outcomes in Self-Expandable or Balloon-Expandable Transcatheter Aortic Valve Replacement.

Elmously A, Gray KD, Truong QA, Burshtein A, Wong SC, de Biasi AR, Worku B, Salemi A.

Cardiology2018;140(2):96-102. doi: 10.1159/000488933. Epub 2018 Jun 29.

PMID:
29961072
Select item 2996075666.

Transcatheter Aortic Valve Replacement in Extremely Large Annuli: (Over)expanding Bioprosthetic Technology to the Limits?

Mehilli J, Jochheim D.

JACC Cardiovasc Interv2018 Jul 23;11(14):1388-1389. doi: 10.1016/j.jcin.2018.05.007. Epub 2018 Jun 27. No abstract available.

PMID:
29960756
Select item 2996075567.

Impact of Aortic Root Anatomy and Geometry on Paravalvular Leak in Transcatheter Aortic Valve Replacement With Extremely Large Annuli Using the Edwards SAPIEN 3 Valve.

Tang GHL, Zaid S, George I, Khalique OK, Abramowitz Y, Maeno Y, Makkar RR, Jilaihawi H, Kamioka N, Thourani VH, Babaliaros V, Webb JG, Htun NM, Attinger-Toller A, Ahmad H, Kaple R, Sharma K, Kozina JA, Kaneko T, Shah P, Hirji SA, Desai ND, Anwaruddin S, Jagasia D, Herrmann HC, Basra SS, Szerlip MA, Mack MJ, Mathur M, Tan CW, Don CW, Sharma R, Gafoor S, Zhang M, Kapadia SR, Mick SL, Krishnaswamy A, Amoroso N, Salemi A, Wong SC, Kini AS, Rodés-Cabau J, Leon MB, Kodali SK.

JACC Cardiovasc Interv2018 Jul 23;11(14):1377-1387. doi: 10.1016/j.jcin.2018.03.034. Epub 2018 Jun 27.

PMID:
29960755
Select item 2995818268.
Select item 2995225269.

Stent fractures after common femoral artery bail-out stenting due to suture device failure in TAVR.

Veulemans V, Afzal S, Ledwig P, Heiss C, Busch L, Sansone R, Soetemann DB, Maier O, Kleinebrecht L, Kelm M, Zeus T, Hellhammer K.

Vasa2018 Jun 28:1-9. doi: 10.1024/0301-1526/a000712. [Epub ahead of print]

PMID:
29952252
Select item 2995183070.

Transcatheter Mitral Valve Replacement: Functional Requirements for Device Design, Bench-Top, and Pre-Clinical Evaluation.

Iyer R, Chalekian A, Lane R, Evans M, Yi S, Morris J.

Cardiovasc Eng Technol2018 Jun 27. doi: 10.1007/s13239-018-0364-z. [Epub ahead of print]

PMID:
29951830
Select item 2994327371.

Gender-dependent association of diabetes mellitus with mortality in patients undergoing transcatheter aortic valve replacement.

Linke A, Schlotter F, Haussig S, Woitek FJ, Stachel G, Adam J, Höllriegel R, Lindner A, Mohr FW, Schuler G, Kiefer P, Leontyev S, Thiele H, Borger MA, Holzhey D, Mangner N.

Clin Res Cardiol2018 Jun 25. doi: 10.1007/s00392-018-1309-0. [Epub ahead of print]

PMID:
29943273
Select item 2994311572.

Transcatheter aortic valve replacement with the 34 mm Medtronic Evolut valve : Early results of single institution experience.

D’Ancona G, Dißmann M, Heinze H, Zohlnhöfer-Momm D, Ince H, Kische S.

Neth Heart J2018 Aug;26(7-8):401-408. doi: 10.1007/s12471-018-1122-4.

Select item 2994136973.

Midterm Outcomes With the Self-Expanding ACURATE neo Aortic Bioprosthesis: The “Bumblebee Paradox” in Transcatheter Aortic Valve Replacement.

Barbanti M, Todaro D.

JACC Cardiovasc Interv2018 Jul 23;11(14):1375-1376. doi: 10.1016/j.jcin.2018.06.004. Epub 2018 Jun 22. No abstract available.

PMID:
29941369
Select item 2993663474.

Atrioventricular and intraventricular block after transcatheter aortic valve implantation.

Lee JJ, Goldschlager N, Mahadevan VS.

J Interv Card Electrophysiol2018 Jun 24. doi: 10.1007/s10840-018-0391-6. [Epub ahead of print]

PMID:
29936634
Select item 2993449375.

Recurrent Unilateral Transudative Pleural Effusion Due to Low Flow, Low Gradient Severe Aortic Stenosis.

Al-Khafaji JF, Taha M, Abdalla AO, Rowan C.

Am J Case Rep2018 Jun 23;19:739-743. doi: 10.12659/AJCR.909448.

Select item 2992964276.

Whose Urgency Is it, Anyway?

Brener SJ.

JACC Cardiovasc Interv2018 Jun 25;11(12):1186-1187. doi: 10.1016/j.jcin.2018.03.035. No abstract available.

PMID:
29929642
Select item 2992964177.

Outcomes Following Urgent/Emergent Transcatheter Aortic Valve Replacement: Insights From the STS/ACC TVT Registry.

Kolte D, Khera S, Vemulapalli S, Dai D, Heo S, Goldsweig AM, Aronow HD, Elmariah S, Inglessis I, Palacios IF, Thourani VH, Sharaf BL, Gordon PC, Abbott JD.

JACC Cardiovasc Interv2018 Jun 25;11(12):1175-1185. doi: 10.1016/j.jcin.2018.03.002. Epub 2018 Mar 11.

PMID:
29929641
Select item 2992963978.

Medium-Term Follow-Up of Early Leaflet Thrombosis After Transcatheter Aortic Valve Replacement.

Ruile P, Minners J, Breitbart P, Schoechlin S, Gick M, Pache G, Neumann FJ, Hein M.

JACC Cardiovasc Interv2018 Jun 25;11(12):1164-1171. doi: 10.1016/j.jcin.2018.04.006.

PMID:
29929639
Select item 2992775879.

Left Subclavian Transcatheter Aortic Valve Replacement Under Combined Interscalene and Pectoralis Nerve Blocks: A Case Series.

Block M, Pitchon DN, Schwenk ES, Ruggiero N, Entwistle J, Goldhammer JE.

A A Pract2018 Jun 18. doi: 10.1213/XAA.0000000000000819. [Epub ahead of print]

PMID:
29927758
Select item 2992620680.

Optimal pre-TAVR annulus sizing in patients with bicuspid aortic valve: area-derived perimeter by CT is the best-correlated measure with intraoperative sizing.

Wang Y, Wang M, Song G, Wang W, Lv B, Wang H, Wu Y.

Eur Radiol2018 Jun 20. doi: 10.1007/s00330-018-5592-y. [Epub ahead of print]

PMID:
29926206
Select item 2992437681.

Immediate improvement of left ventricular mechanics following transcatheter aortic valve replacement.

Lozano Granero VC, Fernández Santos S, Fernández-Golfín C, Plaza Martín M, de la Hera Galarza JM, Faletra FF, Swaans MJ, López-Fernández T, Mesa D, La Canna G, Echeverría García T, Habib G, Martíne Monzonís A, Zamorano Gómez JL.

Cardiol J2018 Jun 20. doi: 10.5603/CJ.a2018.0066. [Epub ahead of print]

Select item 2992312682.

Sex-Specific Considerations in Women with Aortic Stenosis and Outcomes After Transcatheter Aortic Valve Replacement.

Mihos CG, Klassen SL, Yucel E.

Curr Treat Options Cardiovasc Med2018 Jun 19;20(7):52. doi: 10.1007/s11936-018-0651-x. Review.

PMID:
29923126
Select item 2992253583.
Select item 2991587884.

Less pronounced reverse left ventricular remodeling in patients with bicuspid aortic stenosis treated with transcatheter aortic valve replacement compared to tricuspid aortic stenosis.

Xiong TY, Wang X, Li YJ, Liao YB, Zhao ZG, Wei X, Xu YN, Zheng MX, Zhou X, Peng Y, Wei JF, Feng Y, Chen M.

Int J Cardiovasc Imaging2018 Jun 18. doi: 10.1007/s10554-018-1401-6. [Epub ahead of print]

PMID:
29915878
Select item 2991274185.

Predictors of Persistent Tricuspid Regurgitation After Transcatheter Aortic Valve Replacement in Patients With Baseline Tricuspid Regurgitation.

Worku B, Valovska MT, Elmously A, Kampaktsis P, Castillo C, Wong SC, Salemi A.

Innovations (Phila)2018 May/Jun;13(3):190-199. doi: 10.1097/IMI.0000000000000504.

PMID:
29912741
Select item 2991243286.

Transcatheter aortic valve replacement in the setting of left atrial appendage thrombus.

Salemi A, De Micheli A, Aftab A, Elmously A, Chang R, Wong SC, Worku BM.

Interact Cardiovasc Thorac Surg2018 Jun 14. doi: 10.1093/icvts/ivy189. [Epub ahead of print]

PMID:
29912432
Select item 2991133687.

TAVR versus SAVR: Who determines the risk?

Lazar HL.

J Card Surg2018 Jun 17. doi: 10.1111/jocs.13744. [Epub ahead of print] No abstract available.

PMID:
29911336
Select item 2991130788.

Evolving trends in aortic valve replacement: A statewide experience.

Kim KM, Shannon F, Paone G, Lall S, Batra S, Boeve T, DeLucia A, Patel HJ, Theurer PF, He C, Clark MJ, Sultan I, Deeb GM, Prager RL.

J Card Surg2018 Jun 17. doi: 10.1111/jocs.13740. [Epub ahead of print]

PMID:
29911307
Select item 2990896989.

Transcatheter Aortic Valve Replacement on an Aortic Mechanical Valve.

Arzamendi D, Ruiz V, Ramallal R, Alcasena MS, Beunza MT, Larman M.

JACC Cardiovasc Interv2018 Jul 9;11(13):e107-e108. doi: 10.1016/j.jcin.2018.04.046. Epub 2018 Jun 13. No abstract available.

PMID:
29908969
Select item 2990351990.

Transcatheter or surgical treatment of severe aortic stenosis and coronary artery disease: A comparative analysis from the Italian OBSERVANT study.

Barbanti M, Buccheri S, Capodanno D, D’Errigo P, Ranucci M, Rosato S, Santoro G, Fusco D, Tamburino C, Biancari F, Seccareccia F; OBSERVANT Research Group.

Int J Cardiol2018 Jun 7. pii: S0167-5273(17)36915-2. doi: 10.1016/j.ijcard.2018.06.011. [Epub ahead of print]

PMID:
29903519
Select item 2989884891.

Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: The randomized ATLANTIS trial.

Collet JP, Berti S, Cequier A, Van Belle E, Lefevre T, Leprince P, Neumann FJ, Vicaut E, Montalescot G.

Am Heart J2018 Jun;200:44-50. doi: 10.1016/j.ahj.2018.03.008. Epub 2018 Mar 10.

PMID:
29898848
Select item 2989883792.

Utility of an additive frailty tests index score for mortality risk assessment following transcatheter aortic valve replacement.

Steinvil A, Buchanan KD, Kiramijyan S, Bond E, Rogers T, Koifman E, Shults C, Xu L, Torguson R, Okubagzi PG, Pichard AD, Satler LF, Ben-Dor I, Waksman R.

Am Heart J2018 Jun;200:11-16. doi: 10.1016/j.ahj.2018.01.007. Epub 2018 Jan 31.

PMID:
29898837
Select item 2989684793.

Advanced chronic kidney disease: Relationship to outcomes post-TAVR, a meta-analysis.

Makki N, Lilly SM.

Clin Cardiol2018 Jun 12. doi: 10.1002/clc.22993. [Epub ahead of print] Review.

Select item 2989677794.

Comparing outcomes after transcatheter aortic valve replacement in patients with stenotic bicuspid and tricuspid aortic valve: A systematic review and meta-analysis.

Kanjanahattakij N, Horn B, Vutthikraivit W, Biso SM, Ziccardi MR, Lu MLR, Rattanawong P.

Clin Cardiol2018 Jun 12. doi: 10.1002/clc.22992. [Epub ahead of print]

Select item 2989560095.

Stroke and Cardiovascular Outcomes in Patients With Carotid Disease Undergoing Transcatheter Aortic Valve Replacement.

Kochar A, Li Z, Harrison JK, Hughes GC, Thourani VH, Mack MJ, Matsouaka RA, Cohen DJ, Peterson ED, Jones WS, Vemulapalli S.

Circ Cardiovasc Interv2018 Jun;11(6):e006322. doi: 10.1161/CIRCINTERVENTIONS.117.006322.

PMID:
29895600
Select item 2989459496.

Percutaneous access versus surgical cut down for TAVR: Where do we go from here?

Ates I, Cilingiroglu M.

Catheter Cardiovasc Interv2018 Jun;91(7):1363-1364. doi: 10.1002/ccd.27653.

PMID:
29894594
Select item 2989341797.

Inadvertent pacemaker lead dislodgement.

Eulert-Grehn JJ, Schmidt G, Kempfert J, Starck C.

Pacing Clin Electrophysiol2018 Jun 12. doi: 10.1111/pace.13412. [Epub ahead of print]

PMID:
29893417
Select item 2988800998.

Successful Coronary Protection during TAVI in Heavily Calcified Aortic Leaflets in Patient with Short and Low Left Coronary System.

Kabach M, Alrifai A, Lovitz L, Rothenberg M, Faber C, Nores M.

Case Rep Cardiol2018 May 14;2018:2758170. doi: 10.1155/2018/2758170. eCollection 2018.

Select item 2988746499.

Role of T2 mapping in left ventricular reverse remodeling after TAVR.

Gastl M, Behm P, Haberkorn S, Holzbach L, Veulemans V, Jacoby C, Schnackenburg B, Zeus T, Kelm M, Bönner F.

Int J Cardiol2018 Sep 1;266:262-268. doi: 10.1016/j.ijcard.2018.02.029.

PMID:
29887464
Select item 29885699100.

Early changes in N-terminal pro-B-type natriuretic peptide levels after transcatheter aortic valve replacement and its impact on long-term mortality.

Liebetrau C, Gaede L, Kim WK, Arsalan M, Blumenstein JM, Fischer-Rasokat U, Wolter JS, Kriechbaum S, Huber MT, van Linden A, Berkowitsch A, Dörr O, Nef H, Hamm CW, Walther T, Möllmann H.

Int J Cardiol2018 Aug 15;265:40-46. doi: 10.1016/j.ijcard.2018.02.037.

PMID:
29885699

Read Full Post »

Older Posts »